vs

Side-by-side financial comparison of Nano Dimension Ltd. (NNDM) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Nano Dimension Ltd. is the larger business by last-quarter revenue ($57.8M vs $35.5M, roughly 1.6× RECURSION PHARMACEUTICALS, INC.). Nano Dimension Ltd. runs the higher net margin — -171.1% vs -304.2%, a 133.2% gap on every dollar of revenue. Nano Dimension Ltd. produced more free cash flow last quarter ($-21.1M vs $-47.3M).

Nano Dimension Ltd. is a leading provider of additively manufactured electronics solutions and 3D printing technologies. It designs high-precision 3D printers, related materials, and software for producing printed circuit boards, microelectronics components, and multi-layer electronic devices, serving aerospace, defense, medical, automotive, and industrial electronics segments across global markets.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

NNDM vs RXRX — Head-to-Head

Bigger by revenue
NNDM
NNDM
1.6× larger
NNDM
$57.8M
$35.5M
RXRX
Higher net margin
NNDM
NNDM
133.2% more per $
NNDM
-171.1%
-304.2%
RXRX
More free cash flow
NNDM
NNDM
$26.2M more FCF
NNDM
$-21.1M
$-47.3M
RXRX

Income Statement — Q4 FY2024 vs Q4 FY2025

Metric
NNDM
NNDM
RXRX
RXRX
Revenue
$57.8M
$35.5M
Net Profit
$-98.8M
$-108.1M
Gross Margin
43.1%
59.8%
Operating Margin
-155.1%
-304.8%
Net Margin
-171.1%
-304.2%
Revenue YoY
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$-0.45
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NNDM
NNDM
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$5.2M
Q2 25
$19.2M
Q1 25
$14.7M
Q4 24
$57.8M
$4.5M
Q3 24
$26.1M
Q2 24
$28.4M
$14.4M
Q1 24
$13.8M
Net Profit
NNDM
NNDM
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-162.3M
Q2 25
$-171.9M
Q1 25
$-202.5M
Q4 24
$-98.8M
$-178.9M
Q3 24
$-95.8M
Q2 24
$-79.2M
$-97.5M
Q1 24
$-91.4M
Gross Margin
NNDM
NNDM
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
43.1%
-181.4%
Q3 24
53.7%
Q2 24
45.8%
36.2%
Q1 24
19.1%
Operating Margin
NNDM
NNDM
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
-155.1%
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
NNDM
NNDM
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-3135.3%
Q2 25
-894.2%
Q1 25
-1373.3%
Q4 24
-171.1%
-3935.5%
Q3 24
-367.5%
Q2 24
-279.4%
-676.6%
Q1 24
-662.4%
EPS (diluted)
NNDM
NNDM
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$-0.41
Q1 25
$-0.50
Q4 24
$-0.45
$-0.56
Q3 24
$-0.34
Q2 24
$-0.35
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NNDM
NNDM
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$317.2M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$860.0M
$1.1B
Total Assets
$902.5M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NNDM
NNDM
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$317.2M
$594.4M
Q3 24
$427.6M
Q2 24
$231.8M
$474.3M
Q1 24
$296.3M
Total Debt
NNDM
NNDM
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
NNDM
NNDM
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$1.0B
Q2 25
$919.1M
Q1 25
$933.9M
Q4 24
$860.0M
$1.0B
Q3 24
$524.6M
Q2 24
$870.3M
$584.4M
Q1 24
$401.2M
Total Assets
NNDM
NNDM
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$1.4B
Q2 25
$1.3B
Q1 25
$1.3B
Q4 24
$902.5M
$1.4B
Q3 24
$726.5M
Q2 24
$911.0M
$775.9M
Q1 24
$557.8M
Debt / Equity
NNDM
NNDM
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NNDM
NNDM
RXRX
RXRX
Operating Cash FlowLast quarter
$-18.9M
$-46.1M
Free Cash FlowOCF − Capex
$-21.1M
$-47.3M
FCF MarginFCF / Revenue
-36.5%
-133.1%
Capex IntensityCapex / Revenue
3.8%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NNDM
NNDM
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-117.4M
Q2 25
$-76.4M
Q1 25
$-132.0M
Q4 24
$-18.9M
$-115.4M
Q3 24
$-59.2M
Q2 24
$-30.7M
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
NNDM
NNDM
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$-133.8M
Q4 24
$-21.1M
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
NNDM
NNDM
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
-907.4%
Q4 24
-36.5%
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
NNDM
NNDM
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
16.4%
Q1 25
12.4%
Q4 24
3.8%
28.6%
Q3 24
17.5%
Q2 24
8.2%
Q1 24
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons